Structure Therapeutics Inc. (NASDAQ:GPCR - Get Free Report) shares hit a new 52-week low during mid-day trading on Monday . The stock traded as low as $22.22 and last traded at $21.90, with a volume of 216488 shares traded. The stock had previously closed at $23.77.
Wall Street Analyst Weigh In
A number of research analysts recently commented on the stock. Stifel Nicolaus initiated coverage on shares of Structure Therapeutics in a research report on Wednesday, January 8th. They set a "buy" rating and a $50.00 price objective on the stock. JMP Securities reissued a "market outperform" rating and issued a $91.00 price target on shares of Structure Therapeutics in a report on Wednesday, December 18th. Finally, HC Wainwright reissued a "buy" rating and issued a $80.00 price target on shares of Structure Therapeutics in a report on Thursday, December 19th. Eight research analysts have rated the stock with a buy rating, According to MarketBeat, the company presently has an average rating of "Buy" and a consensus target price of $81.29.
Read Our Latest Stock Analysis on GPCR
Structure Therapeutics Stock Performance
The firm has a market capitalization of $1.23 billion, a price-to-earnings ratio of -29.07 and a beta of -2.75. The business's 50-day moving average is $26.80 and its two-hundred day moving average is $33.74.
Institutional Trading of Structure Therapeutics
A number of hedge funds have recently modified their holdings of GPCR. Spire Wealth Management bought a new stake in Structure Therapeutics during the 4th quarter worth approximately $243,000. JPMorgan Chase & Co. increased its position in shares of Structure Therapeutics by 302.3% in the third quarter. JPMorgan Chase & Co. now owns 33,936 shares of the company's stock worth $1,489,000 after purchasing an additional 25,500 shares during the period. Vestal Point Capital LP boosted its position in Structure Therapeutics by 105.4% in the third quarter. Vestal Point Capital LP now owns 1,150,000 shares of the company's stock valued at $50,474,000 after buying an additional 590,000 shares in the last quarter. abrdn plc boosted its position in Structure Therapeutics by 132.7% in the third quarter. abrdn plc now owns 217,083 shares of the company's stock valued at $9,528,000 after buying an additional 123,789 shares in the last quarter. Finally, Barclays PLC lifted its holdings in shares of Structure Therapeutics by 64.5% during the third quarter. Barclays PLC now owns 81,138 shares of the company's stock worth $3,562,000 after purchasing an additional 31,815 shares during the period. 91.78% of the stock is currently owned by institutional investors and hedge funds.
Structure Therapeutics Company Profile
(
Get Free Report)
Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.
Recommended Stories
Before you consider Structure Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Structure Therapeutics wasn't on the list.
While Structure Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
